Procter & Gamble (PG) Files Rule 144 Notice for $1.87M Sale
Rhea-AI Filing Summary
Form 144 notice for Procter & Gamble Company (PG) shows a proposed sale of Common Stock scheduled on 08/21/2025 through Morgan Stanley Smith Barney LLC Executive Financial Services on the NYSE. Two separate lots are listed: 796 shares with an aggregate market value of $125,119.26 and 11,128 shares with an aggregate market value of $1,749,154.68, for a combined market value of $1,874,273.94. The securities were acquired on 08/18/2025 as Performance Stock Program Awards from The Procter & Gamble Company; amounts acquired were 1,725 and 24,091 shares respectively, with payment dates on 08/18/2025. The filer reports no securities sold in the past three months and includes the standard signature representations required by Rule 144.
Positive
- Compliance disclosure filed under Rule 144 with detailed acquisition and broker information
- No sales reported in the prior three months, simplifying aggregation and compliance review
- Securities acquired via Performance Stock Program and listed with acquisition/payment dates, improving transparency
Negative
- None.
Insights
TL;DR: Routine insider sale notice; size appears immaterial to PG's market capitalization.
The filing documents a Rule 144 notice for proposed sales totaling about $1.87 million executed via Morgan Stanley Smith Barney on 08/21/2025. The shares were granted under a performance stock program two days earlier and the filer reports no sales in the prior three months. For a large-cap issuer like PG, this filing represents a routine compliance disclosure rather than a material market-moving event.
TL;DR: Disclosure aligns with Rule 144 requirements and includes required signer representation.
The notice provides acquisition details (dates, grant type, grantor) and broker information, fulfilling transparency expectations for potential insider sales. The statement that no undisclosed material adverse information is known and the absence of recent prior disposals simplify governance review. There is no indication of unusual trading plans or irregularities in the filing text provided.